Guidelines update, v41.1

Version 41.1 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of six new studies on disease-modifying treatments.

• Convalescent plasma – two new studies comparing convalescent plasma to usual care in 912 and 160 patients with moderate-critical COVID-19 (Bégin et al.), (Sekine et al.)
• Hydroxychloroquine – one new study comparing hydroxychloroquine to usual care in 412 patients with critical COVID-19 (REMAP-CAP)
• Lopinavir-ritonavir – one new study comparing lopinavir-ritonavir to usual care in 617 patients with critical COVID-19 (REMAP-CAP)
• Ivermectin – one new study comparing ivermectin to placebo in 501 non-hospitalised people with mild COVID-19 (Vallejos et al.)
• Bamlanivimab plus etesevimab – one new trial comparing bamlanivimab plus etesevimab to placebo in 1035 patients with mild-moderate COVID-19 (Dougan et al.)

Ends.